A5004441435- Malaria Research and Control
- Mosquito-borne diseases and control
- HIV/AIDS Research and Interventions
- Research on Leishmaniasis Studies
- Computational Drug Discovery Methods
- HIV-related health complications and treatments
- HIV Research and Treatment
- Viral Infections and Outbreaks Research
- Parasites and Host Interactions
- Global Maternal and Child Health
- Plant Pathogens and Fungal Diseases
- Nematode management and characterization studies
- HIV/AIDS drug development and treatment
- Influenza Virus Research Studies
- HIV/AIDS Impact and Responses
- Drug-Induced Hepatotoxicity and Protection
- Travel-related health issues
- SARS-CoV-2 and COVID-19 Research
- Pharmaceutical studies and practices
- vaccines and immunoinformatics approaches
- Adolescent Sexual and Reproductive Health
Kenya Medical Research Institute
2011-2022
Wellcome Trust
2022
Juntendo University
2022
University College London
2018
Medical Research Council
2018
Queen Mary University of London
2018
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe in children 5 to 17 months age by approximately 50% an ongoing phase 3 trial. We studied infants 6 12 weeks recruited for the same
Encouraging progress has been seen with reductions in Plasmodium falciparum malaria transmission some parts of Africa. Reduced might lead to increasing susceptibility among older children due lower acquired immunity, and this implications for ongoing control strategies.We conducted a longitudinal observational study admitted Kilifi County Hospital Kenya linked it data on residence insecticide-treated net (ITN) use. This included from 69,104 aged 3 mo 13 y between 1 January 1990 31 December...
Malaria transmission has recently fallen in many parts of Africa, but systematic descriptions infection and disease across all age groups are rare. Here, an epidemiological investigation parasite prevalence, the incidence fevers associated with infection, severe hospitalized mortality among children older than 6 months adults on Kenyan coast is presented.
Many parts of Africa have witnessed reductions in Plasmodium falciparum transmission over the last 15 years. Since immunity to malaria is acquired more rapidly at higher transmission, slower acquisition lower may partially offset benefits transmission. We examined clinical spectrum disease and predictors mortality after sustained changes intensity, using data collected from 1989 2016. conducted a temporal observational analysis 18,000 children, aged 14 days years old, who were admitted...
Triple antimalarial combination therapies combine potent and rapidly cleared artemisinins or related synthetic ozonides, such as arterolane, with two, more slowly eliminated partner drugs to reduce the risk of resistance. We aimed assess safety, tolerability, efficacy arterolane-piperaquine-mefloquine versus arterolane-piperaquine artemether-lumefantrine for treatment uncomplicated falciparum malaria in Kenyan children.
Plasmodium falciparum infections lead to febrile illness unless the host has sufficient immunity, in which case infection may cause no immediate symptoms (ie, "asymptomatic parasitemia"). Previous studies are conflicting on role of asymptomatic parasitemia determining risk developing malaria.
Abstract Background Previous investigations indicate that methotrexate, an old anticancer drug, could be used at low doses to treat malaria. A phase I evaluation was conducted assess the safety and pharmacokinetic profile of this drug in healthy adult male Kenyan volunteers. Methods Twenty five volunteers were recruited admitted receive a 5 mg dose methotrexate/day/5 days. Pharmacokinetics blood sampling carried out 2, 4, 6, 12 24 hours following each dose. Nausea, vomiting, oral ulcers...
Abstract Background In sub-Saharan Africa, data on virologic outcomes of young people living with HIV (YLWH) enrolled antiretroviral therapy (ART) remains scarce. this study, we describe the prevalence virological non-suppression (VNS) and its associated factors among YLWH aged 18–24 years from Kenyan coast. Methods Data were analyzed for 384 who participated in a larger cross-sectional study conducted between November 2018 September 2019 two counties at coast (Kilifi Mombasa). Descriptive...
Reference intervals for clinical laboratory parameters are important assessing eligibility, toxicity grading and management of adverse events in trials. Nonetheless, haematological biochemical used trials sub-Saharan Africa typically derived from industrialized countries, or WHO references that not region-specific. We set out to establish community reference values amongst children aged 4 weeks 17 months Kilifi, Kenya. conducted a cross sectional study nested within phase II III RTS, S...
<ns3:p>Introduction Antimalarial therapeutic efficacy studies are routinely conducted in malaria-endemic countries to assess the effectiveness of antimalarial treatment strategies. Targeted amplicon sequencing (AmpSeq) uniquely identifies and quantifies genetically distinct parasites within an infection. In this study, AmpSeq <ns3:italic>Plasmodium falciparum</ns3:italic> apical membrane antigen 1 (<ns3:italic>ama1</ns3:italic>), multidrug resistance gene (<ns3:italic>mdr1</ns3:italic>),...
Antimalarial therapeutic efficacy studies are routinely conducted in malaria-endemic countries to assess the effectiveness of antimalarial treatment strategies. Targeted amplicon sequencing (AmpSeq) uniquely identifies and quantifies genetically distinct parasites within an infection. In this study, AmpSeq Plasmodium falciparum apical membrane antigen 1 ( ama1), multidrug resistance gene mdr1), were used characterise complexity infection (COI) drug-resistance genotypes, respectively. P....
<ns3:p>Introduction Antimalarial therapeutic efficacy studies are routinely conducted in malaria-endemic countries to assess the effectiveness of antimalarial treatment strategies. Targeted amplicon sequencing (AmpSeq) uniquely identifies and quantifies genetically distinct parasites within an infection. In this study, AmpSeq <ns3:italic>Plasmodium falciparum</ns3:italic> apical membrane antigen 1 (<ns3:italic>ama1</ns3:italic>), multidrug resistance gene (<ns3:italic>mdr1</ns3:italic>),...
<ns3:p>Antimalarial therapeutic efficacy studies are routinely conducted in malaria-endemic countries to assess the effectiveness of antimalarial treatment strategies. Targeted amplicon deep sequencing (TADS) uniquely identifies and quantifies genetically distinct parasites within an infection. In this study, TADS <ns3:italic>Plasmodium falciparum</ns3:italic> apical membrane antigen 1 (<ns3:italic>ama1</ns3:italic>), multidrug resistance gene (<ns3:italic>mdr1</ns3:italic>), were used...